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Abstract  39 
The aim of the present work was to isolate, cultivate, differentiate and conduct cellular 40 
characterization of MSCs derived from equine adipose tissue (eAT) and bone marrow (eBM). 41 
Furthermore, isolated and characterized cells were used in racehorses suffering from a 42 
superficial flexor tendon injury. eAT collection was performed at the base of the horse tail, 43 
while eBM was aspirated from iliac crest. Mononuclear cell fraction was isolated and 44 
cultured. In vitro differentiation and molecular characterization at P3 of culture were 45 
performed. No significant differences were found between DTs (Doubling Time) of all 46 
passages (P>0.05). DT was greater for eBM than for eAT (3.2±1.5 vs 1.3±0.7; P<0.05). 47 
Positive von Kossa and Alizarin Red staining confirmed osteogenesis. Alcian blue and Oil 48 
Red O staining illustrated chondrogenesis and adipogenesis, respectively, in both cell lines. 49 
Furthermore, isolated cells resulted positive for CD90, CD44 and CD105, while were 50 
negative for hematopoietic markers, CD14, CD45 and CD34. Although marker CD73 51 
expresses reaction in other studies involving MSCs in different species, it did not cross-52 
reacted with equine AT and BM mesenchymal stem cells. Using isolated cells for injured 53 
tendon therapy, no adverse reactions were observed and all inoculated horses returned to race 54 
competitions. In vitro results revealed the immunophenotypic characterization of isolated 55 
cells similar to that observed in human mesenchymal stem cells from the same sources; 56 
furthermore, in the present study, their clinical use proves the safety of equine bone marrow 57 
and adipose tissue derived MSCs and a successful outcome of the treated animals that 58 
returned to their previous level of sport activity.  59 
 60 
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1. Introduction 65 
Isolation of mesenchymal stem cells (MSCs) has been described in several species and from 66 
different tissues, including bone marrow [1], peripheral blood [2], adult fat [3] and umbilical 67 
cord blood [4]. International Society for Cellular Therapy has established a minimal criteria 68 
for defining human MSCs [5]. They should adhere to plastic and should be able to 69 
differentiate into osteoblasts, adipocytes and chrondoblasts in vitro. Finally MSCs should 70 
express CD105, CD73 and CD90 and should not express hematopoietic markers such as 71 
CD45, CD34, CD14 or CD11b, CD79a or CD19 and HLA-DR. Unfortunately, and in contrast 72 
to human, no such uniform characterization criteria are available for MSCs from animal 73 
origin in general, and equine origin in specific. In horses, cells from bone marrow (eBM) and 74 
adipose tissue (eAT) have been isolated and some researchers demonstrated their multilineage 75 
differentiation potential by the ability to undergo adipogenic, osteogenic and chondrogenic 76 
differentiation [6-8]. Only few authors determined immunophenotypic characterization of 77 
cells from equine adipose tissue and bone marrow [9] by flow cytometry, as request for 78 
human MSCs by ISCT [5].  79 
Due to similarities in size, load and types of joint injuries suffered by horses and humans, 80 
U.S. Food and Drug Administration indicated the horse as the most appropriate animal model 81 
for testing clinical effects of MSCs therapies for osteoarticular injuries in human [10]. In 82 
addition, the economic and welfare costs of performance-related injuries in horses have 83 
helped to increase the interest in the use of stem cells to accelerate and improve healing [11]. 84 
Therefore, the horse can be considered at the same time an animal model for human 85 
orthopedics injuries and a patient itself [12]. Despite this premise, due to the lack of the 86 
demonstration of stem cells markers or confirmation of stemness through gene expression or 87 
differentiating capacities, in recent years, many racehorses have been treated for orthopedics 88 
injuries with cell mixture improperly called “stem cell” [13].  89 
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The aim of the present work was to isolate, cultivate, differentiate and perform flow 90 
cytometric characterization of MSCs derived from equine adipose tissue (eAT) and bone 91 
marrow (eBM), as postulated by ISCT for human cells. Furthermore, we describe the outcome 92 
of clinical cases of horses admitted to the Department of Veterinary Medical Sciences, 93 
University of Bologna, with an overstrain SDFT (Superficial Digital Flexor Tendon) lesion, 94 
after autologous eAT and eBM MSCs implantation.  95 
 96 
2. Materials and Methods 97 
 98 
2.1 Materials 99 
All chemicals were obtained from Sigma-Aldrich (St. Louis, MO, USA), plastic dishes and 100 
tubes from Sarstedt Inc.(Newton, NC, USA), unless otherwise noted. 101 
 102 
2.2 Animals Ethics 103 
 104 
All stages of the present study were approved by the Ethics Committee at the University of 105 
Bologna and by the Italian Ministry of Health. Before performing any manual skills on the 106 
animals, an informed consent has been signed by the owners. 107 
 108 
2.3 Study Design  109 
Ten racehorses, ranging in age from 2 to 9 years old, referred at the Department of Veterinary 110 
Medical Sciences, University of Bologna, due to an overstrained SDFT, were included in the 111 
present study. There was no control of age, sex or trainer for enrolled animals. The inclusion 112 
criteria were first-time tendon injuries, less than 15 days old, with an ultrasound evaluation of 113 
the cross-sectional area (CSA) >30% and, in longitudinal scans, a Fiber Alignment Score 114 
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(FAS) 2 (target path 25 to 50% parallel). It was recommended that injuries should not be 115 
recurrent but it was not possible to be certain of this for all treated horses. Animals were 116 
randomly assigned to two groups for the harvest of bone marrow (eBM; n=5) and adipose 117 
tissue (eAT; n=5). MSCs from both sources were cultured, and on the passage three (P3), they 118 
were assessed using immunophenotypic characterization by flow cytometry and evaluated for 119 
their differentiation potential into three mesenchymal lineages, as stated by ISCT for human 120 
MSCs. 121 
 122 
2.4 Sampling and MSCs isolation 123 
 124 
2.4.1 Bone Marrow 125 
Bone marrow was aspirated from iliac crest of five animals (4-9 years old). Briefly, after 126 
sedation, with intravenously (IV) injection of detomidine chlorohydrate (10 μ/kg; 127 
Domosedan, Pfizer, Italy) and butorphanol tartrate (0.03 mg/kg; Nargesic ACME, Italy), the 128 
iliac crest was aseptically prepared (hair shaving and skin scrub using 10% povidone-iodine 129 
and denatured alcohol) and 2% lidocaine (Pfizer) was infiltrated into the subcutaneous tissue. 130 
BM samples were collected using 11G BM biopsy needles collected to a heparinized syringes 131 
(Eparina Vister 5000 iu/ml, Marvecspharma; ~1000 IU/10mL BM aspirate). All horses 132 
received NSAIDs (flunixin meglumine, 1.1 mg/Kg IV; Meflosyl, Pfizer) for 3 days after the 133 
procedure. 134 
In laboratory, samples were diluted 1:1 with DPBS (Dulbecco’s Phosphate Buffered Solution 135 
plus 100 iu/ml penicillin and 100 µg/ml streptomycin) and washed by centrifuging at 400 g 136 
(Heraeus Megafuge 1.0R; rotor: Heraeus # 2704), for 10 minutes. Pellet was then re-137 
suspended in 5 ml of DMEM-TCM 199 (1:1), supplemented with 100 iu/ml penicillin, 100 138 
µg/ml streptomycin and 10% FBS (Gibco, Invitrogen) (culture medium). The mononuclear 139 
 7 
cell fraction was isolated by carefully loading cells onto a 70% Percoll gradient and by 140 
centrifuging at 1880 g for 30 minutes. Cells were collected from the interface and washed in 141 
culture medium by three centrifugation at 400 g for 10 minutes. After the last centrifugation, 142 
cells were re-suspended in 1 ml of culture medium and counted by hemocytometer.  143 
 144 
2.4.2 Adipose tissue  145 
For adipose tissue harvesting, horses were sedated as described above and the area over the 146 
dorsal gluteal muscles was aseptically prepared. Skin and subcutaneous tissues were then 147 
desensitized by local infiltration of lidocaine 2% (Pfizer) using an inverted L-block. A 10-15 148 
cm incision was made parallel and ~15 cm abaxial to the vertebral column. Adipose tissue 149 
specimen was then harvested over the superficial gluteal fascia and placed into a 20 mL 150 
polypropylene centrifuge tube, containing sterile DPBS plus antibiotics. The skin incision was 151 
then closed with nylon suture. All horses received NSAIDs (flunixin meglumine, 1.1 mg/Kg 152 
IV; Meflosyl, Pfizer) for 3 days after the procedure. 153 
Under a laminar flow hood, sample tissue was rinsed by repeated immersion in DPBS, 154 
weighed and minced finely (0.5 cm) using sterile scissors. Minced tissue was transferred to a 155 
50 ml polypropylene tube, and 1 ml/1 g sample of a digestion solution (0.1 % [w/v] 156 
collagenase type I [GIBCO®, Invitrogen], dissolved in DMEM-TCM199) was added. The 157 
tissue and digestion solution were mixed thoroughly, incubated in a 37°C water bath for at 158 
least 1 hour, and mixed every 15 minutes. After incubation, collagenase was inactivated by 159 
dilution 1:1 with DPBS plus 10% (v/v) FBS. The solution obtained was filtered and 160 
undigested tissue was discarded. Nucleated cells were pelleted at 400 g for 10 minutes. The 161 
supernatant was discarded, pellet was re-suspended in 5 ml of culture medium and spun at 162 
400 g for 10 minutes to wash cells. This operation was repeated three times. After the last 163 
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wash, cell pellet was re-suspended in 1 ml of culture medium and cell concentration was 164 
counted by hemocytometer. 165 
 166 
2.5 Cell Doubling method 167 
 168 
Primary cells were plated in a 25 cm2 flask, as “Passage 0” (P0), at a density of 5 x 103 169 
cell/cm2 and incubated in a 5% CO2 humidified atmosphere at 38.5°C. The medium was 170 
completely replaced every 3 days until the adherent cell population reached ~80% confluence. 171 
At this point, the adherent primary MSCs were passaged by digestion with 0.25% (w/v) 172 
trypsin, counted with a hemocytometer, and reseeded as P1 at 5 x 103 cells/cm2. For the 173 
subsequent passages, cells were inoculated in 25 cm2 flasks at 5 x 103 cells/cm2 and allowed 174 
to multiply for 6-7 days to 90% confluence before trypsinization and successive passage. 175 
Cell-doubling time (DT), cell culture time (CT) and cell-doubling numbers (CD) were 176 
calculated from hemocytometer counts for each passage according to the following two 177 
formulae [14]:  178 
   CD= ln(Nf/Ni)/ln(2)     (1) 179 
    180 
DT= CT/CD       (2) 181 
where Nf  and Ni are the final and initial number of cells, respectively.  182 
 183 
2.6 Chondrogenic, Osteogenic and Adipogenic in vitro differentiation 184 
 185 
During the third passage (P3) of in vitro culture, undifferentiated eBMMSCs and eATMSCs 186 
were placed in triplicate in six-well plates at density of 5x103 cells/cm2 and induced towards 187 
the chondrogenic, ostegenic and adipogenic lineages, using the protocol previously described 188 
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by our research group for equine MSCs derived from foetal adnexa [15]. Briefly, after 189 
reaching 80% confluence, culture medium was removed and the differentiation media 190 
reported in Table 1 were added to the cultures. Cells in monolayer were incubated for 3 191 
weeks. As a negative control an equal number of cells were cultured in culture medium. In 192 
both groups, the medium was completely replaced every three days. After three weeks of 193 
culture, differentiation was confirmed by appropriate staining. Briefly, to asses chondrogenic 194 
differentiation cells were fixed with 10% (v/v) formalin for 1 h at room temperature (RT), 195 
then stained with Alcian Blue solution (1% in 3% acetic acid (v/v), pH 2.5) for 15 min at RT. 196 
Alcian Blue stains acid mucosubstances and acetic mucins confirming chondrogenic 197 
differentiation cytologically. In the osteogenic assay, latter stage of osteogenesis was assessed 198 
via von Kossa and Alizarin Red staining to detect calcium or calcium salt intracellular 199 
deposits. For von Kossa staining, cells were fixed with 10% (v/v) formalin for 1 h at RT. 200 
They were then washed 5 times with distilled water then 1 ml of 5% (w/v) silver nitrate was 201 
added and cells were exposed to yellow light for 15 min. Calcium-phosphate deposits stained 202 
black. To confirm osteogenic differentiation, Alizarin Red S staining was also used. In brief, 203 
cells were rinsed with DPBS and fixed, incubating in ice-cold ethanol 70% (v/v) for 1h at RT. 204 
After three washes with distilled water, 1 ml of 2% (w/v) Alizarin Red S (pH 4.1-4.3) solution 205 
was added. The plate was incubated at RT for 30 minutes, then Alizarin Red S solution was 206 
removed and cells rinsed four times with distilled water. Calcium deposits stained red. 207 
Finally, to evaluate the baseline formation of neutral lipid-vacuoles in differentiated cells Oil 208 
Red O staining was used. Cells were fixed with 10% (v/v) formalin for 1 hour at RT. The 209 
formalin was then replaced with 2 ml of sterile water. After few minutes, water was replaced 210 
with 60% (v/v) isopropanol, then cells were covered with Oil Red O solution (0.3% in 60% 211 
isopropanol (v/v)). Five minutes later, cells were rinsed with distilled water and lipid vacuoles 212 
appeared red. 213 
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 214 
2.7 Characterization of MSCs 215 
 216 
Cytofluorimetric analysis was performed to identify cell surface marker expression of equine 217 
MSCs. At passage 3 of culture, cells were labeled with the following monoclonal antibodies: 218 
CD105, CD45, CD90, CD44, CD34, CD14 and CD73 (all from Beckman Coulter, Fullerton, 219 
CA). They were also labeled with isotype control antibodies. Briefly, at 80% of confluence, 220 
cells were harvested using 0.25% (w/v) trypsin solution and aliquoted at a concentration of 221 
0.5x106 cells/ml. Each aliquot was fixed and permeabilized using Reagent 1 of Intraprep Kit 222 
(Beckman Coulter, Miami, FL) according to manufacturer's instructions. Cells were stained 223 
for 30 min with either conjugated-specific antibodies or istotype-matched control mouse 224 
immunoglobulin G (Table 2) at recommended concentrations. Labeled cells were washed 225 
twice in DPBS and fluorescence intensity was evaluated using a FC500 two-laser equipped 226 
cytometer (Beckman Coulter, Miami, FL). All analyses were based on control cells incubated 227 
with isotype-specific IgGs to establish the background signal. Cross reactivity of the 228 
antibodies used was screened using cultured human and horse MSCs. Furthermore, to verify 229 
cross-reactivity, control of circulating equine lymphocytes was carried out. The similarity of 230 
CD markers was also identified by comparing the amino acid sequences using Blast (Basic 231 
Local Alignment Search Tool). Results were further analysed with the CXP dedicated 232 
program. 233 
 234 
2.8 Clinical trial 235 
 236 
2.8.1 Cell preparation for implantation 237 
 11 
The day of implantation, 10 ml of autologous whole venous blood was collected using a 238 
syringe pre-loaded with heparin (500 iu/ml of blood). Blood sample was centrifuged at 1500 g 239 
for 15 min. The obtained plasma was used to prepare implantation medium, consisting of 240 
culture medium (without FBS) plus 20% of autologous plasma. 241 
Amplified autologous MSCs were washed three times with DPBS, trypsinized and treated as 242 
described above. After the last wash, pellet was diluted in 1 ml of implantation medium and 243 
cells were counted in a Thoma’s chamber after Trypan Blue staining, to assess cell viability. 244 
The final cell concentration used was 5x106 live MSCs/ml. 245 
 246 
2.8.2 Implantation 247 
All material used in this phase was disposable and sterile (needles, gloves, syringes). Briefly, 248 
this involved an initial ultrasonographic examination to identify the echogenicity of the core 249 
lesion and its extent in order to optimize needle placement for MSCs implantation. Horses 250 
were sedated as described above. The palmar metacarpal region was then aseptically 251 
prepared, then local subcutaneous infiltration of 2% lidocaine has been performed. After that, 252 
the cell suspension was injected into the core lesion under ultrasound guide using a 21 gauge 253 
38-50 mm needle. After implantation, the limb was immediately bandaged to minimize 254 
subcutaneous bleeding and loss of injected cells from the tendon.  255 
 256 
2.8.3 Rehabilitation program 257 
After implantation, a standardized exercise program, as summarized in Table 3, was 258 
prescribed. During this period animals were not treated with any other drug (anti-259 
inflammatory). Repeat ultrasound examinations were performed at day 0 (day of treatment), 260 
7, 15 and 30 after treatment, to highlight possible acute side reactions to cells implantation. 261 
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Twelve months after implantation the follow up was concluded and the ability of enrolled 262 
animals to return to their previous activity was evaluated. 263 
 264 
2.9 Statistical Analysis 265 
 266 
To evaluate animal distribution in both groups and their homogeneity, a T student test for 267 
paired variable (Statistics for Windows, Stat Soft Inc., Tulsa, Oklahoma, USA) was 268 
performed. 269 
Cell-doubling time, cell-doubling number and CD expression rate are expressed as mean ± 270 
standard deviation. Statistical analysis was performed using Statistics for Windows (Stat Soft 271 
Inc., Tulsa, Oklahoma, USA). Data were analysed using one-way analysis of variance 272 
(ANOVA) for multiple comparisons. Significance has been assessed for P<0.05. 273 
The CSA and FAS data were reported as median and range. Kruscal Wallis test was 274 
performed to compare the value of CSA and FAS registered at day 0, 7, 15 and 30 after 275 
treatment. The analysis was performed with Medcalc, Version 12.3, and the statistically 276 
significant threshold was set up as P< 0.05 277 
 278 
3. Results 279 
 280 
3.1 Sampling and Cellular Growth 281 
 282 
The technique used for the isolation and cultivation of MSCs derived from equine adipose 283 
(eAT) tissue and bone marrow (eBM) was proved to be safe and viable. No complications 284 
have been registered after bone marrow and adipose tissue recover.  285 
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All of the isolated cells from eAT and eBM adhered to the culture flasks on the first day of 286 
culture. Adhesion was observed within 48 hours for eBMMSCs and 24 hours for eATMSCs, 287 
and adherent cells were fibroblast-like and spindle shaped, forming a highly homogenous 288 
monolayer (Fig. 1A; Fig. 1B). During eight consecutive passages, CD of the eATMSCs was 289 
linearly increased (Fig. 2A), while eBMMSCs showed an increase of CD only until P5 (Fig. 290 
2B). Since P0 to P8, eATMSCs showed a mean doubling time (DT) of 1.3±0.7 days/CD 291 
(range: 0.8-3.2 days). By P8, total mean CD was 37.3±4.6. The mean DT showed by 292 
eBMMSCs (P0-P5) was 3.2±1.5 days/CD (range: 0.5-5 days) and it was statistically higher 293 
than that showed by equine ATMSCs (P<0.05). By P5, eBMMSCs cell doubling number was 294 
26.2±5.0. This result was not statistically different from the CD registered at P5 of equine 295 
ATMSCs (P>0.05). No lag phase has been observed during the in vitro culture of both cell 296 
lines: in fact no statistically significant differences in the number of CD have been registered 297 
among different culture passages (P>0.05).  298 
 299 
3.2 Immunophenotypic characterization by flow cytometry 300 
 301 
Due to no-equine specific antibodies for flow cytometry are present, in this study we used 302 
anti-human antibodies, routinely employed by Immunohaematology and Transfusion Center 303 
Equipe, Sant’Orsola Hospital, using cross-reactivity of antibodies among different species. 304 
The antibodies efficiency was verified by performing a control on circulating equine 305 
lymphocytes (data not shown). As expected, considering the results obtained with human 306 
lymphocytes, adult and hematopoietic markers used have not been expressed by these cells. 307 
Unexpected data has been registered for CD45 and CD73, that were negative also for 308 
lymphocytes (data not shown). Furthermore, we compared amino acid sequences using Blast 309 
(Basic Local Alignment Search Tool). Results are summarized in Table 4. In particular, cells 310 
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of both evaluated lines were reactive to surface markers CD90 and CD105. MSCs also 311 
demonstrated a marked reaction to CD44, a cell-surface glycoprotein having a role in MSCs 312 
migration. Typical hematopoietic cells marker (CD14) was not expressed, while there was a 313 
weak expression of CD34. Due to negative lymphocytes CD45 and CD73 expression and the 314 
lack of horse CD45 and CD73 sequence, for these markers cross-reactivity could not be 315 
confirmed, as well as its negative expression by equine BM and ATMSCs. 316 
 317 
3.4 In vitro Differentiation 318 
 319 
According with ISCT, we induced chondrogenic, osteogenic and adipogenic differentiation 320 
culturing each lineage for three weeks in induction media. 321 
After three weeks of culture in chondorgenic and osteogenic induction medium, cells isolated 322 
from both tissues clearly changed their morphology from adherent monolayer of swirling 323 
spindle-shaped cells to layered cells clusters surrounded by matrix-like substance positive 324 
upon Alcian Blu (Fig. 3A; Fig. 3B) and von Kossa and Alizarin Red (Fig. 3E-H), 325 
respectively. Controls, kept in regular culture medium, showed no change in morphology and 326 
no cells stained positive (Fig. 3C-D; Fig. 3I-L). Intracytoplasmic lipid droplets were stained 327 
using Oil Red O after 21 days of in vitro culture; lipid accumulations were higher in cells 328 
cultured in adipogenic differentiation medium (Fig. 3M-N) compared to control culture (Fig. 329 
3O-P). However, eATMSCs showed a greater adipogenic potential than eBMMSCs, 330 
characterized by a larger accumulation of lipid vacuoles (Fig. 3M-N).  331 
 332 
3.5 Clinical outcome after eBM and eATMSC treatment 333 
 334 
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Clinical evaluation was carried both on short term (day 0 to 30 after cell injection), to 335 
highlight possible acute side reactions to cells implantation, and long term (12 months), to 336 
evaluate the ability of enrolled animals to return to their previous activity. Autologous 337 
eATMSCs and eBMMSCs implantation, re-suspended in cultured medium plus 20% of 338 
autologous plasma, did not induce any deleterious effect on the treated tissue, neither 339 
lameness, local swelling, inflammatory responses (heat or pain on palpation) or formation of 340 
abnormal tissue, detectable with ultrasound examination. No adverse reactions have been 341 
observed in any treated animal by clinical examination during the rehabilitation period.  342 
The value of CSA registered at day 0 (inoculation) and 7, after treatment, resulted statistically 343 
higher than that observed 30 days after cells inoculation (Table 5; P<0.05). The same trend 344 
has been registered for FAS (Table 5; P<0.05). No statistically significant differences in the 345 
mean value of CSA and FAS have been registered between animals treated with eBMMSCs 346 
and eATMSCs (P>0.05). Twelve months after, no sign of lesion could be detected in injured 347 
tendon and fibers showed a correct alignment and a well-organized longitudinal pattern and 348 
one year after lesion occurred, all animals enrolled in the present study returned to racing.  349 
 350 
4. Discussion 351 
Several sources have been studied for obtaining equine MSCs [6,8,15]. However, bone 352 
marrow and adipose tissue are the most studied sources of MSCs in this species [9, 17, 18]. 353 
While bone marrow aspiration from sternum is considered as a quick and innocuous method 354 
of harvest, there have been case reports of accidental fatal thoracic and cardiac puncture [19] 355 
and nonfatal pneumopericardium [20] during bone marrow aspiration from the sternum. 356 
Although these cases are rare, they probably resulted from poor appreciation of local 357 
topographical anatomy at the aspiration site and hence a failure to identify the appropriate site 358 
and depth of needle placement [21]. Some Authors reported a site injuries also after adipose 359 
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tissue collection [22]. In the present study, no side effect have been observed after adipose 360 
tissue and bone marrow harvest, demonstrating that the surgical collection of adipose tissue 361 
from the base of the tail and the aspiration of bone marrow from iliac crest are viable and safe 362 
for animals. Obtained results verified the adherence of eATMSCs and eBMMSCs in culture 363 
in <48 hours, a fact in agreement with reports in previously published data concerning the 364 
characteristics of these cells to adhere to plastic when maintained in culture conditions [8, 17]. 365 
Different from other Authors [14], in the present study, cells isolated from bone marrow and 366 
adipose tissue did not show a lag phase during their in vitro culture. However, while previous 367 
researches did not report a significantly different proliferation rate between eBMMSCs and 368 
eATMSCs [17] or show a higher doubling time for eATMSCs [8], in the present study cells 369 
isolated from equine adipose tissue are characterized by a lower DT compared with cells 370 
isolated from equine bone marrow cultured under the same in vitro conditions. Furthermore, 371 
different from eBMMSCs, eATMSCs can be grown for longer time in vitro. These 372 
characteristics could be very important for using these cells for autologous therapy. Right 373 
now, autologous therapy with MSCs is widely used because, as shown by the present study, it 374 
does not result in any significant deleterious effects at the time of implantation or later, and 375 
shows anti-inflammatory and immunosuppressive effects [23]. However, treatment with 376 
autologous MSCs has limitations, such as in acute injuries, because expansion of MSCs by 377 
culturing takes different days. Cellular growing data registered by us, similar healing time and 378 
no side effects registered in both groups, would make adipose tissue an advantageous source 379 
for cellular therapy. Moreover, since no side effects have been observed using these cells for 380 
allogenic therapy [unpublished data, 24], it would make adipose tissue also an important 381 
MSCs resource for allogenic bank. 382 
Minimum criteria for the characterization of human MSCs, postulated by ISCT [5], consider 383 
not only the ability of cells to adhere to the plastic when maintained in vitro and their 384 
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proliferation rate. In fact, an important feature of MSCs is the expression of markers CD105, 385 
CD73, and CD90 and the lack for markers CD45, CD34, CD14, the human leukocyte antigen-386 
DR surface molecules. Furthermore, as postulated by Dominici et al [5], human MSCs should 387 
present the capacity to differentiate into osteoblasts, adipocytes, and chondroblasts in vitro. In 388 
the present study, eAT and eBM were used as sources for obtaining equine MSCs, and the 389 
MSCs’ expression of surface markers and their differentiation potential into osteogenic, 390 
adipogenic and chondrogenic lineages were evaluated, as stated for human MSCs. All these 391 
determinations were performed at the third passage of in vitro culture because the cells 392 
reached homogeneous culture at this point, as demonstrated by previous studies [15, 18]. In 393 
our study, differentiation into osteoblasts was confirmed by staining calcium deposits with 394 
Alizarin red and Von Kossa. The osteogenic differentiation in equine MSCs was faster than in 395 
other species, including human [25], porcine [26] (Zou et al. 2008) and bovine [27] 396 
(Bosnakovski et al. 2005) and similar to horses [14]. We cultured isolated cells in adipogenic 397 
medium supplemented with 15% of rabbit serum, as recently reported also by our research 398 
group for equine MSCs isolated by foetal adenexa [15]. In fact, it was found that rabbit serum 399 
enhanced adipogenesis in vitro for human [28], rat and mouse [29] MSCs. Rabbit serum has a 400 
high content of free fatty acids, which are putative ligands of PPARy and may thus enhance 401 
adipogenesis. Recently, Ranera et al [18], comparing different induction media for adipogenic 402 
differentiation of equine MSCs, found that only the medium supplemented with 15% rabbit 403 
serum was able to induce adipogenic differentiation. Other authors did not find necessary the 404 
addition of rabbit serum to achieve any reliable adipogenesis [30]. The intracellular 405 
accumulation of red-stained lipid droplets on Day 21 of culture was indicative of adipogenic 406 
differentiation. However, cytoplasmic droplets were already visible within the first few days 407 
of culture. This characteristic was in agreement with findings observed by other authors [8, 408 
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30]. Different from that observed in another study [18], in the present research equine MSCs 409 
did not display an adipogenic potential lower than other species. 410 
As a final step in the differentiation process, we demonstrated that equine MSCs had tri-411 
lineage potential since cells were able to differentiate into chondrocytes. Cells isolated from 412 
eAT showed a higher differentiation potency as demonstrated by a greater accumulation of 413 
glycosaminoglycans, calcium salt and lipid droplet, comparing with cells isolated from eBM 414 
and cultured under the same differentiation condition. These results are not in agreement with 415 
those that proved the lack of significant differences between the two lines [31] or reported 416 
that osteogenic and chondrogenic differentiation can be better in eBMMSCs [32,33]. Further 417 
studies could be conducted to assess the differentiation potential of eAT and eBMMSCs in 418 
other lineages of therapeutic interest, such as myocytes, and further investigation are needed 419 
using quantitative PCR to confirm a distinct differentiation potential between adipose and 420 
bone marrow derived cells.  421 
Different from previous studies [18, 31], during the present experiment, the 422 
immunophenotypic characterization of the surface of the MSCs used was conducted, by flow 423 
cytometry, with the same markers considered in humans, excepted for equine leukocyte 424 
antigen-DR surface molecules because of the lack of equine specific monoclonal antibodies 425 
available and evidence that certain markers from other species do not cross-react with the 426 
equine species [34]. To provide evidence for inter-species cross-reactivity, the similarity of 427 
CD markers between human and equine, was identified comparing the amino acid sequence, 428 
as suggested by de Mattos Carvalho et al. [35], and we used equine circulating lymphocytes 429 
as control [15]. The immunophenotypic investigation was conducted only by flow cytometry, 430 
and PCR was not employed. In fact, although this technique shows the mRNA expression of 431 
different markers, this expression is not always correlated with the presence of protein, 432 
therefore with stemness. However, mRNA expression detection by PCR may possibly 433 
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complement the results obtained. In agreement with our previous report in horses [15], eBM 434 
and eAT, cultured under the same conditions, showed high positivity for CD90 and CD44. 435 
CD90, called Thy-1, is an antigen present in established culture of equine MSC. The 436 
expression profile of these markers in equine BM- and AT-MSCs at passage 3, was in 437 
accordance with the immunophenotype reported for human MSCs by ISCT [5]. The CD44 438 
antigen is a cell-surface glycoprotein involved in cell–cell interactions, cell adhesion and 439 
migration. Data observed in the present study confirm those previously reported, by our team, 440 
for MSCs isolated from equine foetal adnexa [15]. Relatively low CD105 expression relative 441 
to CD90 and CD44 by both MSCs lines has been previously reported in equine by Xie et al 442 
[36]. CD105 (endoglin) is a high affinity co-receptor for transforming growth factor (TGF)-β1 443 
and TGF-β3 [37]. Although CD105 is generally considered an important marker for MSCs [5] 444 
several reports showed that its expression vary depending upon MSC source, culture time in 445 
vitro and differentiation state [38,39]. In human and mouse the existence of a heterogeneous 446 
cell population CD105 positive and CD105 negative have been recently demonstrated [40, 447 
41]. Furthermore, since CD105 is a component of the TGF-β receptor, its presence or absence 448 
on the MSCs must have an effect on their response to TGF-β. In particular, MSCs 449 
constitutively secrete TGF-β1 in culture and the fetal bovine serum contains high levels of 450 
latent TGF-β1 [40, 42], so the expression of this protein could be related to the culture 451 
medium composition, and in particular to the presence of serum, as observed recently in 452 
human by Mark et al [43]. A lack of reactivity with haematopoietic markers CD14, which 453 
cross-reaction was confirmed by lymphocytes investigation, indicates that isolated cells are 454 
negative for haematopoietic progenitors. On the other hand isolated cells showed a weak 455 
expression of CD34 in both eAT and eBMMSCs, despite in a higher percentage compared 456 
with the findings of Ranera et al [9] but without statistically significant differences between 457 
the two lineages. Another study on equine MSCs from adipose tissue and bone marrow stated 458 
 20 
its lack in these lineages [31]. Because the immunoreactivity for CD34 in human AT-MSCs 459 
declines with passages [44,45], further analysis is necessary to confirm that the loss of CD34 460 
in equine MSCs is similar to that in human cells. Furthermore, the lack of reactivity of equine 461 
cells and lymphocytes with the haematopoietic markers CD45 and MSC with marker CD73 462 
probably indicates that the human-directed reagents do not cross-react with their 463 
corresponding equine epitopes. These findings need further investigation to assess if, in 464 
particularly, the lack of CD73 expression is due to the lack of cross-reactivity or is a species-465 
specific feature, due to the same findings in previous studies conducted both on eATMSCs 466 
and on foetal MSCs [15, 46]. However, taken together, the results obtained in the present 467 
study support an MSC phenotype from both tissue sources used in this investigation.  468 
No significant increase in lesion cross-sectional area or pain sensitivity occurred after the 469 
implantation of adipose and bone marrow derived MSCs, which is in agreement with the 470 
results reported by Fortier and Smith [47], who indicated that the implantation of bone 471 
marrow-derived MSCs did not provoke worsening of the lesion or even tendon reaction, with 472 
no increase in tendon area in ultrasonographic imaging. The dose of progenitor cells used in 473 
this study (5x106 cells) is lower than that used by other Authors [48]. At present, there are no 474 
published studies evaluating the optimal number of MSCs that should be used in the treatment 475 
of tendinitis, though one recent report suggests that murine MSCs are potentially cytotoxic 476 
when injected in high concentrations directly into tumor tissue (melanoma), liberating several 477 
angiogenesis inhibitor agents that induce apoptosis and annul tumor growth, a process that 478 
would be of enormous potential in cancer therapy [49]. Whether the administration of high 479 
concentrations of MSCs in tendon injuries stimulates the release of angiogenesis inhibitors 480 
remains unknown, though this occurs, it could result in the inhibition of tendon healing, 481 
which is not desirable. In the present study, the use of eAT and eBMMSCs proved to be safe 482 
with the absence of neoplastic tissue formation at the lesion site where the implantation was 483 
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performed during the experiment. Analysis of the results of the ultrasonographic evaluation of 484 
the tendons is in agreement with previously published reports [48]. Furthermore, different 485 
from Barreira et al. [50], no ultrasonographic differences in the mean values of the percentage 486 
of ruptured collagen fibers in a cross-sectional view have been observed after the 487 
administration of MSCs. In our experiment, all ultrasonographic imaging was obtained by the 488 
same operator using the same ultrasound equipment, to avoid variation due to different 489 
operators and the use of different equipment. This precaution is extremely important because 490 
it was demonstrated that significant interoperator variability can occur when measuring the 491 
area of the same tendon [51]. Despite the positive results obtained in the present study we are 492 
aware that it has some limitations. In the present study owned horses with overstrain SDF 493 
injuries have been enrolled, no control group was included neither an animal treated as 494 
clinical case has been subjected to histological examination, differently from studies 495 
performed in experimental animals [48, 50].  496 
Different Authors, for treating induced tendon lesions, performed the implantation of 497 
mononucleated cells, derived from adipose and bone marrow tissue, 48 hours after harvest, 498 
and they called the mix of cells “stem cells”, though MSCs are present in small quantities. In 499 
our study, autologous adipose tissue and bone marrow-derived MSCs isolated, expanded in 500 
vitro and characterized have been used. Our choice involves greater cost, it is more laborious, 501 
and obviously the application requires a delay in the therapy needed for cell expansion in 502 
vitro. However, it has an advantage in that the procedure permits isolation and expansion of 503 
the number of MSCs, thereby avoiding the administration of a heterogenous cell population 504 
that can disturb the process of tendon repair [52].  505 
5. Conclusion 506 
The panel of surface antigens tested by flow cytometry in the present study revealed a similar 507 
phenotypic profile between horse and human MSCs, although specific differences in some 508 
 22 
surface antigens were noticed. A similar cell surface profile was also observed between 509 
eBMMSCs and eATMSCs. This findings are important for characterizing these cells before 510 
using them for cellular-based therapies in equine medicine. However, many questions still 511 
remain, and further investigation will be necessary to clarify the mechanisms and functions of 512 
stem cell epitopes, such as the effect of marker expression variation on the pluripotency of 513 
MSCs or the study of their expression by cells from different passages. Furthermore, though 514 
further investigation are needed using a higher number of animals, our clinical data confirm 515 
that eAT and eBMMSCs could be used in clinical trials involving both autologous and 516 
allogeneic therapy in horses. Under the experimental conditions of this study, the eATMSCs 517 
showed higher in vitro differentiation and cell growth. These findings suggest that eAT may 518 
be preferable for cell banking purposes. 519 
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Table 1. Media used for inducing adipogenic, osteogenic and chondrogenic differentiation of 690 
cells isolated from eAT and eBM. 691 





100 IU/ml penicillin, 100 μg/ml 
streptomycin 






100 IU/ml penicillin, 100 μg/ml 
streptomycin, 1 μM dexamethasone (for 6 
days), 0.5 mM isobutyl-methylxanthine (for 
3 days), 10 mM insulin, 0.2 mM 
indomethacin 





100 IU/ml penicillin, 100 μg/ml 
streptomycin, 10 mM β- glycerophosphate, 
0.1 μM dexamethasone, 50 μM ascorbic 
acid 





100 IU/ml penicillin, 100 μg/ml 
streptomycin, 6.25 μg/ml insulin, 50 mM 
ascorbic acid, 0.1 μM dexamethasone, 10 




Table 2. Primary antibodies and Isotypes used for flow cytometry. 693 
Markers Primary antibody Ig 
CD44FITC Mouse monoclonal IgG1 
CD90PC5 Mouse monoclonal IgG1 
CD105PE Mouse monoclonal IgG2a 
CD73PE Mouse monoclonal IgG1 
CD14PC5 Mouse monoclonal IgG2a 
CD45APC Mouse monoclonal IgG1 
Isotype   
Isotype PC5 Mouse monoclonal IgG2a 
Isotype FITC Mouse monoclonal IgG1 
Isotype PE Mouse monoclonal IgG1 
Isotype APC Mouse monoclonal IgG1 




Table 3. Rehabilitation program after cell inoculation. 697 
Week after cell inoculation Exercise program 
1 Box rest 
2-4 Hand walk 10 min twice/day 
5-9 Hand walk 20 min twice /day 
10-16 Hand walk 30-40 min twice /day 
17-25 
Hand walk 40 min twice /day and trot 5-30 
min/day 




Table 4. Flow cytometry analysis of eATMSCs and eBMMSCs at Passage 3 of in vitro 700 
culture. Summarizing table. 701 
Tissue CD90 CD105 CD73 CD44 CD14 CD34 CD45 
eAT 69.5±8.4 70.5±1.8 0.2±0.3 91.9±8.9 0.6±0.3 5.8±4.8 3.0±4.2 




Table 5. Cross Sectional Area (CSA) and Fibers Alignment Score (FAS): median and range 704 



























Figure Legends 707 
Figure 1. Monolayer of rapidly expanding adherent spindle-shaped fibroblastoid cells 708 
compatible with undifferentiated mesenchymal stem cell. Adipose Tissue (A), Bone Marrow 709 
(B). Magnification x 10.  710 
 711 
Figure 2. Cell doubling time and number of cultured primary and passaged mesenchymal 712 
stem cells. All values reflect the mean ± standard deviation. A-B: Adipose Tissue. C-D: Bone 713 
Marrow. 714 
 715 
Figure 3. Overlay histograms of cytometry analysis. In black isotypic controls are 716 
represented. Empty histograms represent the analysis with mAbs on mesenchymal cell 717 
culture. 718 
 719 
Figure 4. In vitro differentiation studies. (A) Chondrogenic induction in eATMSCs over three 720 
weeks: Alcian Blue staining of glycosaminoglycans in cartilage matrix. (B) Chondrogenic 721 
induction in eBMMSCs over three weeks: Alcian Blue staining of glycosaminoglycans in 722 
cartilage matrix. (C)-(D) Chondrogenic control: eAT and eBM MSCs cultured in regular 723 
medium for 21 days maintained normal morphology and stained negative for Alcian Blue. (E) 724 
Osteogenic induction in eATMSCs over three weeks: von Kossa staining of extensive 725 
extracellular calcium deposition. (F) Osteogenic induction in eBMMSCs over three weeks: 726 
von Kossa staining of extensive extracellular calcium deposition. (G) Osteogenic induction in 727 
eATMSCs over three weeks: Alizarin Red staining of extensive extracellular calcium 728 
deposition. (H) Osteogenic induction in eBMMSCs over three weeks: Alizarin Red staining 729 
of extensive extracellular calcium deposition. (I)-(J) Osteogenic control: eAT and eBM MSCs 730 
cultured in standard medium for 21 days maintained normal morphology and stained negative 731 
 36 
for von Kossa staining. (K)-(L): Osteogenic control: eAT and eBM MSCs cultured in regular 732 
medium, after 21 days presented normal morphology and stained negative for Alizarin Red 733 
staining. (M) Adipogenic induction in eATMSCs over three weeks: Oil red O staining of 734 
extensive intracellular lipid droplet accumulation. (N) Adipogenic induction in eBMMSCs 735 
over three weeks: Oil red O staining of extensive intracellular lipid droplet accumulation. (O)-736 
(P) Adipogenic control: eATMSCs and eBMMSCs, after 21 days of culture in standard 737 
medium presented normal morphology and stained negative for Oil red O staining.  738 
